| Width: | 200px |
| Width2: | 200px |
| Type: | combo |
| Drug Name: | Carbidopa / oxitriptan |
| Component1: | Carbidopa |
| Class1: | Aromatic L-amino acid decarboxylase inhibitor |
| Component2: | Oxitriptan |
| Class2: | Serotonin precursor |
| Routes Of Administration: | Oral administration |
| Synonyms: | Carbidopa/5-hydroxytryptophan; Carbidopa/L-5-hydroxytryptophan; Carbidopa/5-HTP; Carbidopa/L-5-HTP; EVX-101 |
Carbidopa/oxitriptan (developmental code name EVX-101), or carbidopa/5-hydroxytryptophan (carbidopa/5-HTP), is a combination of 5-hydroxytryptophan (oxitriptan), a serotonin precursor, and carbidopa, a peripherally selective aromatic L-amino acid decarboxylase inhibitor, which is under development as an antidepressant for the treatment of depressive disorders.[1] As of June 2020, it is in phase 1 clinical trials for this indication.